funded by the National Natural Science Foundation of China(Grant Nos.:82004081 and 52073145);the National Natural Science Foundation of Nanjing University of Chinese Medicine,China(Grant No.:NZY82004081).
The treatment of non-small cell lung cancer(NSCLC)remains a challenge due to tumor evolution during anti-angiogenesis therapies,in which the mechanism of vascular mimicry(VM)is believed to result in ineffective treatm...
supported by the Nature Science Foundation of Hubei Province(No.2017CFB606).
Objective Aberrant activating mutations in cyclin-dependent kinases 4 and 6(CDK4/6)are common in various cancers,including gastroesophageal malignancies.Although CDK4/6 inhibitors,such as abemaciclib and palbociclib,h...